

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
26 September 2002 (26.09.2002)

PCT

(10) International Publication Number
WO 02/074759 A1

- (51) International Patent Classification⁷: **C07D 307/93**, A61K 31/343, A61P 35/00
- (74) Agents: **ARNETT, Stephen, E.** et al.; Perkins Coie LLP, P.O. Box 2168, Menlo Park, CA 94026 (US).
- (21) International Application Number: **PCT/US02/07834**
- (22) International Filing Date: 14 March 2002 (14.03.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/276,617 15 March 2001 (15.03.2001) US
- (71) Applicant (for all designated States except US): **PHARMAGENESIS, INC.** [US/US]; 3182 Porter Drive, Palo Alto, CA 94304 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **DAI, Dongcheng** [CN/US]; 367 Easy Street, Apt. A, Mountain View, CA 94043 (US). **FIDLER, John, M.** [US/US]; 6399 Girvin Drive, Oakland, CA 94611 (US). **MUSSER, John, H.** [US/US]; 23 Michael Court, San Carlos, CA 94070 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: AMINO ACID DERIVATIVES OF TRIPTOLIDE COMPOUNDS AS IMMUNE MODULATORS AND ANTICANCER AGENT



(I)

(57) Abstract: Compounds which are prodrugs of triptolide or its derivatives, containing an amino acid or oligopeptide moiety, are used for anticancer or immunosuppressive treatment. The compounds are of the structure (I) where X^1 is OH or OR^1 , and X^2 and X^3 are independently OH, OR^1 or H, with the proviso that at least one of X^1 , X^2 , and X^3 is OR^1 , and at least one of X^2 and X^3 is H; and R^1 is selected from the group consisting of: (a), (b): $C(=O)CHY-NHP^1$, (c): $C(=O)CH(NHP^1)-(CH_2)_m-C(=O)OP^2$,

(d): $C(=O)(CH_2)_n-CH(NHP^1)-C(=O)OP^2$ and (e): $[C(=O)CHY-NH]_z-C(=O)CHY-NHP^1$; where Y is a side chain of a naturally occurring amino acid or a one- or two-carbon homolog thereof; P^1 is selected from the group consisting of H, $C(=O)OR^2$, and $C(=O)R^3$, where each of R^2 and R^3 is independently H, alkyl, alkenyl, aryl or aralkyl; m is an integer from 0-5; n is an integer from 0-5; z is an integer from 2-10; and P^2 is selected from the group consisting of H, alkyl, alkenyl, aryl or aralkyl.

WO 02/074759 A1

**Amino Acid Derivatives of Triptolide Compounds as
Immune Modulators and Anticancer Agents**

Field of the Invention

- 5 The present invention relates to immunomodulation or anticancer treatment using compounds which are prodrugs of triptolide or its derivatives.

References

- Gleichmann, E. *et al.*, *Immunol. Today* **5**:324 (1984).
- 10 Kocienski, P.J., PROTECTING GROUPS, Georg Thieme Verlag, Stuttgart (1994).
- Korngold, R. and Sprent, J., *J. Exp. Med.* **148**:1687 (1978).
- Kupchan, S.M. *et al.*, *J. Am. Chem. Soc.* **94**:7194 (1972).
- Kupchan, S.M. *et al.*, U.S. Patent No. 4,005,108 (1977).
- Lipsky *et al.*, U.S. Patent No. 5,294,443 (1994).
- 15 Ma *et al.*, *J. Chin. Pharm. Sci.* **1**:12 (1992).
- Murase, N. *et al.*, *Transplantation* **55**:701 (1993).
- Ono and Lindsey, *J. Thor. Cardiovasc. Surg.* **57**(2):225-29 (1969).
- Pu, L. *et al.*, *Zhongguo Yaoli Xuebao* **11**:76 (1990).
- Wang, J. and Morris, R.E., *Transplantation Proc.* **23**:699 (1991).
- 20 Zheng *et al.*, *Zhongguo Yixue Kexueyuan Xuebao* **13**:391 (1991).
- Zheng *et al.*, *Zhongguo Yixue Kexueyuan Xuebao* **16**:24 (1994).

Background of the Invention

- A number of compounds derived from the Chinese medicinal plant *Tripterygium*
- 25 *wilfordii* (TW) have been identified as having immunosuppressive activity, *e.g.* in the treatment of autoimmune disease, and in treating or preventing transplantation rejection, including the treatment of graft-versus-host disease (GVHD), a condition in which transplanted marrow cells attack the recipient's cells. See, for example, co-owned U.S. Patent Nos. 6,150,539 (Triptolide prodrugs having high aqueous solubility), 5,962,516
- 30 (Immunosuppressive compounds and methods), 5,843,452 (Immunotherapy composition and method), 5,759,550 (Method for suppressing xenograft rejection), 5,663,335 (Immunosuppressive compounds and methods), and 5,648,376 (Immunosuppressant diterpene compound), and references cited therein. Such compounds have also been

reported to show anticancer activity. See, for example, Kupchan *et al.*, 1972, 1977, as well as copending and co-owned US application no. 09/766,156.

Triptolide, 16-hydroxy triptolide, triptophenolide, triptidiolide, and celastrol are representative compounds isolated from TW (see *e.g.* Lipsky *et al.*, 1994; Zheng *et al.*, 1991, 1994; Ma *et al.*, 1992). However, the low water solubility of these compounds has limited their ready administration and therapeutic effectiveness. It would be desirable to have immunosuppressive compounds with improved water solubility and low toxicity. In addition, it would be desirable for such compounds to exhibit immunosuppressive activity in their water-soluble form, or to be convertible to an immunosuppressive form by metabolic processes *in vivo*.

It would also be desirable to have as part of the xenobiotic compound moieties that are naturally sensitive to metabolic processes. The inclusion of an L-amino acid moiety in the structure of the prodrug is expected to render it more susceptible to certain types of metabolic processes, thereby releasing an active moiety with altered and more rapid kinetics.

Conversely, in some applications it would be desirable to have as part of the xenobiotic compound moieties that are naturally resistant to metabolic processes. The inclusion of a D-amino acid moiety in the structure of the prodrug may render it more resistant to certain types of metabolic processes, thereby releasing an active moiety with altered and possibly slower kinetics.

The inclusion of an amino acid moiety in the structure of the prodrug may also alter absorption into the body when administered by a route other than intravenously. The amino acid moiety may also alter the biodistribution of the agent, giving it better access to organs, tissues, tumors, or areas of the body where therapy is useful or desired, or better access to cells, their outer membranes or cell interiors. The amino acid moiety may also alter the excretion of the prodrug, thereby altering the level in the body and the biodistribution, and/or alter bioavailability, by altering binding to blood components (such as albumin) or other tissues.


The inclusion of multiple amino acid moieties as an oligopeptide may be used to target the prodrug to cancer or immune regulatory cells. Targeted prodrugs that bind to specific molecular sites near, on, or in cancer cells, or are selectively transported within these cells, have the potential to significantly decrease side effects associated with anti-

tumor drug administration. In addition, prodrugs that are selectively converted by tumor-specific enzymes (as determined *e.g.* by screening extent of conversion by preparations of such enzymes) can also reduce such side effects, in that they are converted to their active form only in the proximity of the tumor target.

- 5 Likewise, targeted prodrugs that bind to immune regulatory cells, such as T-cells, B-cells or lymphocytes, or are selectively transported into these cells, have the potential to significantly decrease side effects associated with immunosuppressant drug administration. Thus, conjugation of olipeptides to triptolide or triptolide related molecules may result in enhanced drug localization, showing an improved efficacy and
- 10 toxicity profile compared to that of the triptolide alone.

Summary of the Invention




The present invention includes, in one aspect, a compound having the structure:




15 where

X^1 is OH or OR^1 , and X^2 and X^3 are independently OH, OR^1 or H, with the proviso that at least one of X^1 , X^2 and X^3 is OR^1 , and at least one of X^2 and X^3 is H; and

R^1 is selected from the group consisting of:



(c)



(d)

and

(e): $[C(=O)CHY-NH]_z-C(=O)CHY-NHP^1$

where:

- Y is a side chain of a naturally occurring amino acid or a one- or two-carbon
 5 homolog thereof;
 P^1 is selected from the group consisting of H, $C(=O)OR^2$, and $C(=O)R^3$, wherein
 each of R^2 and R^3 is independently H, alkyl, alkenyl, aryl, or aralkyl;
 m is an integer from 0-5;
 n is an integer from 0-5; and
 10 z is an integer from 2-10.

P^2 is selected from the group consisting of H, alkyl, alkenyl, aryl, and aralkyl.


In one embodiment, P^1 and P^2 are non-hydrogen. In further embodiments of this
 category, R^2 and R^3 are also non-hydrogen; *i.e.* selected from alkyl, alkenyl, aryl, and
 aralkyl.

- 15 In selected embodiments, "alkyl" and "alkenyl" are lower alkyl and alkenyl,
 containing one to six carbon atoms; in other embodiments, "alkyl" and "alkenyl" are fatty
 alkyl and alkenyl, containing about 10 to 24, preferably about 12 to 18, carbon atoms.

The chiral α -carbon bearing the nitrogen atom, in each of groups (a) - (d), is of the L
 (naturally occurring) configuration, the D configuration, or a mixture thereof. In selected
 20 embodiments, this carbon is of the L configuration. In other embodiments, this carbon is
 of the D configuration.

In preferred embodiments, Y is a side chain of a naturally occurring amino acid.

In selected embodiments, $X^2 = X^3 = H$. In further embodiments of this class, R^1 is
 selected from



where P^1 is preferably $C(=O)R^3$.

In other aspects, the invention provides methods of anticancer treatment and of
 effecting immunosuppression. In accordance with these methods, a compound in

accordance with claim 1, or a pharmaceutically acceptable salt thereof, is administered to a subject in need of such treatment. In selected embodiments, the anticancer treatment is treatment of colon cancer, breast cancer, lung cancer, or prostate cancer.

Immunosuppressive treatments include inhibition of transplant rejection, inhibition of
5 graft-versus-host disease, and treatment of autoimmune disease, such as rheumatoid arthritis.

These and other objects and features of the invention will become more fully apparent when the following detailed description of the invention is read in conjunction with the accompanying drawings.

10

Detailed Description of the Invention

I. Definitions

The terms below have the following meanings unless indicated otherwise.

A "naturally occurring amino acid" is one of the following, referred to by full name
15 or by standard single-letter or three-letter notation: A, Ala, alanine; C, Cys, cysteine; D, Asp, aspartic acid; E, Glu, glutamic acid; F, Phe, phenylalanine; G, Gly, glycine; H, His, histidine; I, Ile, isoleucine; K, Lys, lysine; L, Leu, leucine; M, Met, methionine; N, Asn, asparagine; P, Pro, proline; Q, Gln, glutamine; R, Arg, arginine; S, Ser, serine; T, Thr, threonine; V, Val, valine; W, Trp, tryptophan; X, Hyp, hydroxyproline; and Y, Tyr,
20 tyrosine. Naturally occurring amino acids are of the L configuration. However, a compound bearing "a side chain of a naturally occurring amino acid" need not be of a particular configuration.

Unless otherwise stated, the amino acid moieties utilized in the compounds of the present invention can be of either the L- (naturally occurring) or D-configuration or can
25 be mixtures of the D- and L-isomers, including racemic mixtures.

"Alkyl" refers to a fully saturated acyclic monovalent radical containing carbon and hydrogen, which may be branched or a straight chain, typically having 1 to about 24 carbon atoms. Higher alkyl or "fatty" alkyl groups include those having about 10 to 24, in one embodiment 12 to 18, carbon atoms. "Lower alkyl" refers to an alkyl radical of 1
30 to 6 carbon atoms, as exemplified by methyl, ethyl, n-butyl, i-butyl, t-butyl, isoamyl, n-pentyl, and isopentyl.

"Alkenyl" refers to an unsaturated acyclic monovalent radical containing carbon and

hydrogen, which may be branched or a straight chain. The alkenyl group may be monounsaturated or polyunsaturated.

"Aryl" refers to a substituted or unsubstituted monovalent aromatic radical, generally having a single ring (*e.g.*, benzene) or two condensed rings (*e.g.*, naphthyl). Monocyclic
5 aryl groups are generally preferred. The term includes heteroaryl groups, which are aromatic ring groups having one or more nitrogen, oxygen, or sulfur atoms in the ring, such as furyl, pyrrole, pyridyl, and indole. By "substituted" is meant that one or more ring hydrogens in the aryl group is replaced with a group or groups preferably selected from fluorine, chlorine, bromine, methyl, ethyl, hydroxy, hydroxymethyl, nitro, amino,
10 methylamino, dimethylamino, methoxy, halomethoxy, and halomethyl.


"Aralkyl" refers to an alkyl, preferably lower (C_1 - C_4 , more preferably C_1 - C_2) alkyl, substituent which is further substituted with an aryl group; examples are benzyl and phenethyl. Also included is fluorenylmethyl, a component of the widely employed Fmoc (fluorenylmethoxycarbonyl) protecting group.

15 The term 'oligopeptide' refers to combinations of 2 to 10 amino acids in peptide linkages.

The term "pharmaceutically acceptable salt" encompasses carboxylate salts having organic and inorganic cations, such as alkali and alkaline earth metal cations (for example, lithium, sodium, potassium, magnesium, barium and calcium); ammonium; or
20 organic cations, for example, dibenzylammonium, benzylammonium, 2-hydroxyethylammonium, bis(2-hydroxyethyl) ammonium, phenylethylbenzylammonium, and the like. Other cations encompassed by the above term include the protonated form of procaine, quinine and N-methylglucosamine, and the protonated forms of basic amino acids such as glycine, ornithine, histidine, phenylglycine, lysine, and arginine.

25 The term also includes salts formed by standard acid-base reactions with basic groups, such as amino groups, having a counterion derived from an organic or inorganic acid. Such counterions include chloride, sulfate, phosphate, acetate, succinate, citrate, lactate, maleate, fumarate, palmitate, cholate, glutamate, glutarate, tartrate, stearate, salicylate, methanesulfonate, benzenesulfonate, sorbate, picrate, benzoate, cinnamate,
30 and the like.

For the purposes of the current disclosure, the following numbering scheme is used for triptolide and triptolide analogs:



A "triptolide compound" can include triptolide (having a single hydroxyl group at C-14), triptiolide (2-hydroxy triptolide), or 16-hydroxytriptolide.


5

II. Immunomodulating and Anticancer Agents

As noted above, triptolide compounds and various derivatives and prodrugs have been shown to have immunosuppressive activity in the treatment of autoimmune disease, and in treating or preventing transplantation rejection, including the treatment of graft-versus-host disease (GVHD), a condition in which transplanted marrow cells attack the recipient's cells. See, for example, co-owned U.S. Patent Nos. 6,150,539 (Triptolide prodrugs having high aqueous solubility), 5,962,516 (Immunosuppressive compounds and methods), 5,843,452 (Immunotherapy composition and method), 5,759,550 (Method for suppressing xenograft rejection), 5,663,335 (Immunosuppressive compounds and methods), and 5,648,376 (Immunosuppressant diterpene compound), and references cited therein. Such compounds have also been reported to show anticancer activity. See, for example, Kupchan *et al.*, 1972, 1977, as well as copending and co-owned US application no. 09/766,156.

The low water solubility of the unmodified compounds, *e.g.* of unmodified triptolide, has limited their ready administration and therapeutic effectiveness. Accordingly, the authors have provided derivatives of these compounds having improved aqueous solubility as well as high therapeutic activity. See U.S. Patent Nos. 6,150,539, 5,962,516, and 5,663,335, cited above. However, none of these disclosed amino acid- or oligopeptide- containing prodrugs.

Preferred amino acid- or oligopeptide-derivatized compositions of the invention have the structure I:




I


where

X^1 is OH or OR^1 , and X^2 and X^3 are independently OH, OR^1 or H, with the proviso that at least one of X^1 , X^2 and X^3 is OR^1 , and at least one of X^2 and X^3 is H; and


5 R^1 is selected from the group consisting of:



10 (b): $C(=O)CHY-NHP^1$



(c)



(d)

and

(e): $[C(=O)CHY-NH]_z-C(=O)CHY-NHP^1$;

15 where:

Y is a side chain of a naturally occurring amino acid or a one- or two-carbon homolog thereof;

P^1 is selected from the group consisting of H, $C(=O)OR^2$, and $C(=O)R^3$, wherein each of R^2 and R^3 is independently H, alkyl, alkenyl, aryl, or aralkyl;

20 m is an integer from 0-5;

n is an integer from 0-5; and

z is an integer from 2-10.

P^2 is selected from the group consisting of H, alkyl, alkenyl, aryl, and aralkyl.

In one embodiment, P^1 and P^2 are non-hydrogen. In further embodiments of this category, R^2 and R^3 are also non-hydrogen; *i.e.* selected from alkyl, alkenyl, aryl, and aralkyl.

In selected embodiments, "alkyl" and "alkenyl" are lower alkyl and alkenyl,
5 containing one to six carbon atoms; in other embodiments, "alkyl" and "alkenyl" are fatty alkyl and alkenyl, containing about 10 to 24, preferably about 12 to 18, carbon atoms.

As noted above, "aryl" refers to a substituted or unsubstituted monovalent aromatic radical, generally having a single ring (*e.g.*, benzene) or two condensed rings (*e.g.*, naphthyl). Monocyclic aryl groups are generally preferred. The term includes heteroaryl
10 groups, which are aromatic ring groups having one or more nitrogen, oxygen, or sulfur atoms in the ring, such as furyl, pyrrole, pyridyl, and indole. By "substituted" is meant that one or more ring hydrogens in the aryl group is replaced with a group or groups preferably selected from fluorine, chlorine, bromine, methyl, ethyl, hydroxy, hydroxymethyl, nitro, amino, methylamino, dimethylamino, methoxy, halomethoxy, and
15 halomethyl. In selected embodiments, the aryl group (including aralkyl) is a hydrocarbon group which is unsubstituted or substituted a group or groups selected from fluorine, chlorine, bromine, methyl, ethyl, methoxy, halomethoxy, and halomethyl.

In each of groups (a) - (e), the chiral carbon(s) bearing the nitrogen atom(s) are of either the D- or the L- configuration, or may include a mixture of the two configurations,
20 including a racemic mixture. In selected embodiments, the configuration is L; in other embodiments, the configuration is D.

Note that, in group (b), the "side chain" can be hydrogen, as in the amino acid glycine. In preferred embodiments of group (b), Y is a side chain of a naturally occurring amino acid. A "one- or two-carbon homolog thereof" is a side chain producing by
25 adding or deleting one or two methylene (CH_2) moieties from a naturally occurring side chain. For example, such homologs of the alanine side chain (methyl) would be ethyl and propyl. Such homologs of the lysine side chain (4-aminobutyl) would include 3-aminopropyl, 5-aminopentyl, and 4-amino-3-methyl butyl. Of these homologs, one-carbon homologs are preferred.

30 In any of groups (a) - (e), the amine nitrogen (the terminal amine in group (e)) may bear a further carboxyl or acyl group (*i.e.* where P^1 is $C(=O)OR^2$ or $C(=O)R^3$), thus forming a carbamate or an amide, respectively.

The compounds are derivatives of triptolide (having a single hydroxyl group at C-14), triptiolide (2-hydroxy triptolide), or 16-hydroxytriptolide. In selected embodiments, the compounds are derivatives of triptolide, having a single hydroxyl group at C-14, *i.e.* where $X^2 = X^3 = H$.

- 5 In one embodiment, R^1 is defined by group (e) above. In further embodiments, R^1 is selected from groups (c) and (d) above. In a still further embodiment, R^1 is represented by group (c). In these embodiments, when P^1 is $C(=O)OR^2$ or $C(=O)R^3$, R^2 and R^3 are preferably selected from alkyl and aralkyl.

- The compound may be provided as a pharmaceutically acceptable salt; *i.e.* a
10 protonated amine salt having an anionic counterion, a carboxylate salt having a cationic counterion, or a zwitterion.

- The compounds possess greater water solubility and modified bioprocessing as compared to the non-derivatized starting compounds, and are useful as prodrugs for immunosuppressive, anti-inflammatory, and anticancer applications, as described further
15 below.

- Higher water solubility is particularly desirable for prodrugs administered intravenously, *e.g.* in anticancer treatment. Alternatively, in immunosuppressive treatment, particularly for chronic conditions, oral administration is generally preferred, and the prodrugs may be designed to have a higher degree of lipid solubility than those intended for
20 intravenous administration. Such prodrugs preferably include non-hydrogen substituents for the variables P^1 and/or P^2 above.

III. Synthesis

- Compounds in accordance with the present invention, as defined by Formula I above,
25 may be prepared from triptolide, triptiolide, or 16-hydroxytriptolide, which can be obtained from the root xylem of the Chinese medicinal plant *Tripterygium Wilfordii* (TW) or from other known sources. The TW plant is found in the Fujian Province and other southern provinces of China; TW plant material can generally be obtained in China or through commercial sources in the United States. Methods for preparing triptolide, triptiolide, and
30 16-hydroxytriptolide are known in the art and are described, for example, in Kupchan *et al.* (1972); Kupchan *et al.* (1977); Lipsky *et al.* (1994); Pu *et al.* (1990); and Ma *et al.* (1992).

The derivatives of the invention are prepared, in general, by condensation of the

hydroxylated triptolide parent compound material with the carboxylic acid functionality of an amino acid, or an activated derivative such as an acid chloride (R^1Cl) or anhydride ($R^1OC(O)R$, where R is lower alkyl, typically methyl). Reactions with the carboxylic acid are typically carried out in the presence of a coupling agent such as

5 dicyclohexylcarbodiimide (DCC) and a catalytic amount of an acylation catalyst such as 4-(dimethylamino)pyridine (DMAP). Any free amino groups in the amino acid can be protected using any of a variety of well known protecting groups, such as tBOC or FMOC. Alternatively, for compounds such as shown in groups (c), group (d), or group (b) where P^1 is $C(=O)OR^2$ or $C(=O)R^3$, the amine is reacted with a carboxylic acid ($R^3C(O)OH$) or

10 carbonate ($R^2OC(O)OH$), or activated derivative thereof, to form the amide or carbamate derivative, respectively. Any other reactive groups, such as active amino acid side chains, are also protected, according to well known methods.

Compounds of group (c) and (d) can be prepared using α -amino diacid starting materials. In each case, a diacid, such as malonic, succinic, glutaric, adipic, heptanedioic, or

15 octanedioic ($m=0-5$ in group (d)) having one α -amino group, which may be derivatized or protected, is used. N-protected cyclic anhydrides of such compounds, such as 2-formamido succinic anhydride or 2-acetamido glutaric anhydride, may also be used. Reaction of the hydroxylated starting material (*i.e.* the triptolide compound) with the carboxyl moiety adjacent to the amino (or protected amino) group produces compounds of group (c), while

20 reaction with the carboxyl moiety more remote from the amino group produces compounds of group (d). When mixtures are produced, they may be separated if desired by standard methods such as chromatography.

Protected α -amino acids suitable for these reactions are frequently commercially available, or they can be prepared by known methods, including known methods of

25 asymmetric synthesis, optical resolution, or chromatography on chiral supports, if necessary. The development of such methods has been an active field of research for many years and is the subject of many articles, books and treatises. The amino compounds may be readily converted to the amide or carbamate derivatives discussed above, if desired.

30 Compounds of group (e) can be prepared using oligopeptides which are derivatized or protected except for the C-terminal carboxyl group. Such oligopeptides can be synthesized by well known methods and are frequently commercially available. Reaction of the

hydroxylated starting material (*i.e.* the triptolide compound) with the C-terminal carboxyl moiety of the oligopeptide produces compounds of group (e). When mixtures are produced, they may be separated if desired by standard methods such as chromatography.

The preparation of several C-14 triptolide derivatives in accordance with the invention
5 is described in the Examples, below.

In cases where all available hydroxyl groups on the starting material are to be derivatized, an excess of the carboxylic acid or active derivative may be used to drive the reaction to completion. The compound 16-hydroxytriptolide contains two free hydroxyl groups, one secondary (at C-14) and one primary (at C-16). Since the hydroxyl group at the
10 16-position is more reactive than the 14-hydroxyl group for steric reasons, mono- and diester derivatives can be selectively made using appropriate reaction conditions. Reaction with a stoichiometric amount of a selected carboxylic acid yields the monoester derivatized at the 16-position, with the 14-hydroxyl group remaining free. Reaction with an excess of the carboxylic acid is effective to derivatize both hydroxyl groups, affording the diester.

15 Monoester derivatives substituted at the more hindered (secondary) hydroxyl group can be prepared by first selectively protecting the less hindered (primary) hydroxyl group, carrying out the condensation reaction with the selected carboxylic acid at the unprotected position, and then removing the protecting group. Suitable hydroxyl protecting groups are well known, and are described, for example, by Kocienski (1994).

20 Selective single derivatization of triptolide (2-hydroxytriptolide) is more difficult because of the similar reactivities of the two secondary hydroxyls. Accordingly, the 2- and 14-monoesters may be prepared as a mixture either by (1) reacting triptolide with a comparable amount of carboxylic acid (*e.g.*, 1 to 3 equivalents) or (2) briefly reacting triptolide with excess carboxylic acid followed quickly by addition of excess alcohol (*e.g.*,
25 ethanol) to quench the excess carboxylic acid. In either case, a mixture of mono- and diester forms can be obtained which may then be separated by standard chromatographic methods such as HPLC.

Metal salts and amine salts of the amino and carboxyl ester compounds of the invention are readily prepared by reaction or exchange with an appropriate counterion.

30

IV. Prodrug Conversion in Serum

Several compounds of formula I were prepared, as described in the Examples. In

preliminary assays, the compounds were evaluated for their capacity to induce apoptosis in cells from the Jurkat human T lymphocyte cell line, after incubation with pooled human serum for 48 hrs at 37°C (see Example 7). One of the compounds was also analyzed for its capacity to inhibit IL-2 production in Jurkat human T lymphocyte cells (see Example 8). Controls consisted of the compounds incubated in complete tissue culture medium (RPMI 1640 medium plus 5 % heat-inactivated fetal calf serum, 1% HEPES, 1% pen/strep, 1% glutamine) rather than human serum.

The results of the assays are presented in Table 1. The ED₅₀ / IC₅₀ values (column 3) are calculated directly from the data in each experiment, and the % conversion values (column 4) are calculated as percent of the ED₅₀ or IC₅₀ value produced by triptolide, incubated in the same plasma (*i.e.* in the same experiment).

Table 1.
Apoptosis/IL-2 inhibition assay analysis of prodrug conversion to bioactive drug

	Compound	ED ₅₀ (nM) after 48 hr incubation with human serum	Conversion (relative activity compared to PG490) (%)
TdT Apoptosis Assay	PG657	300	10
	PG658	750	4.0
	PG659	80	38
	PG660	1100	2.7
Annexin Apoptosis Assay	PG661	34661	0.16
IL-2 Inhibition Assay	PG661	330 (IC ₅₀)	1.4

In these preliminary results, it can be noted that the compound in which the amino acid moiety had no amine or carboxyl substitution (that is, P¹ and P² are both hydrogen; compound PG661, as prepared in Example 6) was converted at a substantially lower rate than compounds with alkyl or aralkyl substitution at the amino acid nitrogen and carboxyl groups. While not wishing to be bound by theory, it is possible that these hydrocarbon regions promote substrate recognition of the compounds by esterases, such as phospholipase A2, which have binding regions both for the ester group and for the neighboring lipid component(s) of glycerol ester-based phospholipids.

V. Therapeutic Compositions

Formulations containing the triptolide analogs of the invention may take the form of

solid, semi-solid, lyophilized powder, or liquid dosage forms, such as tablets, capsules, powders, sustained-release formulations, solutions, suspensions, emulsions, ointments, lotions, or aerosols, preferably in unit dosage forms suitable for simple administration of precise dosages. The compositions typically include a conventional pharmaceutical
5 carrier or excipient and may additionally include other medicinal agents, carriers, or adjuvants. Preferably, the composition will be about 0.5% to 75% by weight of a compound or compounds of the invention, with the remainder consisting of suitable pharmaceutical excipients. For oral administration, such excipients include pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium
10 saccharine, talcum, cellulose, glucose, gelatin, sucrose, magnesium carbonate, and the like. If desired, the composition may also contain minor amounts of non-toxic auxiliary substances such as wetting agents, emulsifying agents, or buffers.

The composition may be administered to a subject orally, transdermally or parenterally, *e.g.*, by intravenous, subcutaneous, intraperitoneal, or intramuscular
15 injection. For use in oral liquid preparation, the composition may be prepared as a solution, suspension, emulsion, or syrup, being supplied either in liquid form or a dried form suitable for hydration in water or normal saline. For parenteral administration, an injectable composition for parenteral administration will typically contain the triptolide analog in a suitable intravenous solution, such as sterile physiological salt solution.

20 Liquid compositions can be prepared by dissolving or dispersing the triptolide analog (about 0.5% to about 20%) and optional pharmaceutical adjuvants in a carrier, such as, for example, aqueous saline, aqueous dextrose, glycerol, or ethanol, to form a solution or suspension. The high water solubility of the compounds of the invention make them particularly advantageous for administering in aqueous solution, *e.g.* by intraperitoneal
25 injection. Although aqueous solutions are preferred, compositions in accordance with the invention may also be formulated as a suspension in a lipid (*e.g.*, a triglyceride, a phospholipid, or a polyethoxylated castor oil such as "CREMOPHOR ELTM"), in a liposomal suspension, or in an aqueous emulsion.

The compound may also be administered by inhalation, in the form of aerosol
30 particles, either solid or liquid, preferably of respirable size. Such particles are sufficiently small to pass through the mouth and larynx upon inhalation and into the bronchi and alveoli of the lungs. In general, particles ranging from about 1 to 10 microns

in size, and preferably less than about 5 microns in size, are respirable. Liquid compositions for inhalation comprise the active agent dispersed in an aqueous carrier, such as sterile pyrogen free saline solution or sterile pyrogen free water. If desired, the composition may be mixed with a propellant to assist in spraying the composition and
5 forming an aerosol.

Methods for preparing such dosage forms are known or will be apparent to those skilled in the art; for example, see Remington's Pharmaceutical Sciences (19th Ed., Williams & Wilkins, 1995). The composition to be administered will contain a quantity of the selected compound in a pharmaceutically effective amount for effecting
10 immunosuppression in a subject.

VI. Immunomodulating and Antiinflammatory Treatment

The compositions of the present invention are useful in applications for which triptolide has proven effective, *e.g.* in immunosuppression therapy, as in treating an
15 autoimmune disease, preventing transplantation rejection, or treating or preventing graft-versus-host disease (GVHD). Triptolide and the present analogs are also useful for treatment of other inflammatory conditions, such as traumatic inflammation, and in reducing male fertility.

Immunosuppressive activity of compounds *in vivo* can be evaluated by the use of
20 established animal models known in the art. Such assays may be used to evaluate the relative effectiveness of immunosuppressive compounds and to estimate appropriate dosages for immunosuppressive treatment. These assays include, for example, a well-characterized rat model system for allografts, described by Ono and Lindsey (1969), in which a transplanted heart is attached to the abdominal great vessels of an allogeneic
25 recipient animal, and the viability of the transplanted heart is gauged by the heart's ability to beat in the recipient animal. A xenograft model, in which the recipient animals are of a different species, is described by Wang (1991) and Murase (1993). A model for evaluating effectiveness against GVHD involves injection of normal F₁ mice with parental spleen cells; the mice develop a GVHD syndrome characterized by
30 splenomegaly and immunosuppression (Korngold, 1978; Gleichmann, 1984). Single cell suspensions are prepared from individual spleens, and microwell cultures are established in the presence and absence of concanavalin A to assess the extent of mitogenic

responsiveness.

The method is useful for inhibiting rejection of a solid organ transplant, tissue graft, or cellular transplant from an incompatible human donor, thus prolonging survival and function of the transplant, and survival of the recipient. This use would include, but not
5 be limited to, solid organ transplants (such as heart, kidney and liver), tissue grafts (such as skin, intestine, pancreas, gonad, bone, and cartilage), and cellular transplants (such as cells from pancreas, brain and nervous tissue, muscle, skin, bone, cartilage and liver).

The method is also useful for inhibiting xenograft (interspecies) rejection; *i.e.* in preventing the rejection of a solid organ transplant, tissue graft, or cellular transplant
10 from a non-human animal, whether natural in constitution or bioengineered (genetically manipulated) to express human genes, RNA, proteins, peptides or other non-native, xenogeneic molecules, or bioengineered to lack expression of the animal's natural genes, RNA, proteins, peptides or other normally expressed molecules. The invention also includes the use of a composition as described above to prolong the survival of such a
15 solid organ transplant, tissue graft, or cellular transplant from a non-human animal.

In another aspect, the invention includes a method of treatment or prevention of graft-versus-host disease, resulting from transplantation into a recipient of matched or mismatched bone marrow, spleen cells, fetal tissue, cord blood, or mobilized or
otherwise harvested stem cells. The dose is preferably in the range 0.25-2 mg/kg body
20 weight/day, preferably 0.5-1 mg/kg/day, given orally or parenterally.

Also included are methods of treatment of autoimmune diseases or diseases having autoimmune manifestations, such as Addison's disease, autoimmune hemolytic anemia, autoimmune thyroiditis, Crohn's disease, diabetes (Type I), Graves' disease, Guillain-Barre syndrome, systemic lupus erythematosus (SLE), lupus nephritis, multiple sclerosis,
25 myasthenia gravis, psoriasis, primary biliary cirrhosis, rheumatoid arthritis and uveitis, asthma, atherosclerosis, Type I diabetes, psoriasis, and various allergies. In treating an autoimmune condition, the patient is given the composition on a periodic basis, *e.g.*, 1-2 times per week, at a dosage level sufficient to reduce symptoms and improve patient comfort. For treating rheumatoid arthritis, in particular, the composition may be
30 administered by intravenous injection or by direct injection into the affected joint. The patient may be treated at repeated intervals of at least 24 hours, over a several week period, or longer, following the onset of symptoms of the disease in the patient. For

extended treatment, oral administration is typically preferred.

For therapy in transplantation rejection, the method is intended particularly for the treatment of rejection of heart, kidney, liver, cellular, and bone marrow transplants, and may also be used in the treatment of GVHD. The treatment is typically initiated
5 perioperatively, either soon before or soon after the surgical transplantation procedure, and is continued on a daily dosing regimen, for a period of at least several weeks, for treatment of acute transplantation rejection. During the treatment period, the patient may be tested periodically for immunosuppression level, *e.g.*, by a mixed lymphocyte reaction involving allogenic lymphocytes, or by taking a biopsy of the transplanted tissue.

- 10 In addition, the composition may be administered chronically to prevent graft rejection, or in treating acute episodes of late graft rejection. As above, the dose administered is preferably 1-25 mg/kg patient body weight per day, with lower amounts being preferred for parenteral administration, and higher amounts for oral administration. The dose may be increased or decreased appropriately, depending on the response of the
15 patient, and over the period of treatment, the ability of the patient to resist infection.

The compounds are also useful as potentiators when administered concurrently with another immunosuppressive drug for immunosuppressive treatments as discussed above.

- A conventional immunosuppressant drug, such as cyclosporin A, FK506, azathioprine, rapamycin, mycophenolic acid, or a glucocorticoid, may thus be administered in an
20 amount substantially less (*e.g.* 20% to 50% of the standard dose) than when the compound is administered alone. Alternatively, the triptolide analog and immunosuppressive drug are administered in amounts such that the resultant immunosuppression is greater than what would be expected or obtained from the sum of the effects obtained with the drug and triptolide analog used alone. Typically, the
25 immunosuppressive drug and potentiator are administered at regular intervals over a time period of at least 2 weeks.

- The compositions and method of the invention are also useful for the treatment of inflammatory conditions such as asthma, both intrinsic and extrinsic manifestations. For treatment of asthma, the composition is preferably administered via inhalation, but any
30 conventional route of administration may be useful. The composition and method may also be used for treatment of other inflammatory conditions, including traumatic inflammation, inflammation in Lyme disease, psoriasis, chronic bronchitis (chronic

infective lung disease), chronic sinusitis, sepsis associated acute respiratory distress syndrome, Behcet's disease, pulmonary sarcoidosis, pemphigus, pemphigoid inflammatory bowel disease, and ulcerative colitis.

The compositions of the invention may also be administered in combination with a
5 conventional anti-inflammatory drug (or drugs), where the drug or amount of drug administered is, by itself, ineffective to induce the appropriate suppression or inhibition of inflammation.

The dose that is administered is preferably in the range of 1-25 mg/kg patient body weight per day, with lower amounts being preferred for parenteral administration, and
10 higher amounts being preferred for oral administration. Optimum dosages can be determined by routine experimentation according to methods known in the art.

VII. Anticancer Treatment

Triptolide prodrugs have shown effectiveness in cancer treatment. See, for example,
15 copending and co-owned US application no. 09/766,156, which describes high efficacy of a triptolide prodrug, in comparison to 5-FU and CPT-11, in studies with tumor xenografts of the HT-29 human colon cancer cell line. The triptolide prodrug (a 14-succinate derivative of triptolide) strongly inhibited tumor growth, to a significantly greater degree than 5-FU and CPT-11, and induced tumor regression.

20 The invention thus includes the use of compositions as described above to treat cancers, including cancers involving cells derived from reproductive tissue (such as Sertoli cells, germ cells, developing or more mature spermatogonia, spermatids or spermatocytes and nurse cells, germ cells and other cells of the ovary), the lymphoid or immune systems (such as Hodgkin's disease and non-Hodgkin's lymphomas), the
25 hematopoietic system, and epithelium (such as skin and gastrointestinal tract), solid organs, the nervous system, and musculo-skeletal tissue. The triptolide prodrugs may be used for treatment of various cancer cell types, including, but not limited to, breast, colon, small cell lung, large cell lung, prostate, malignant melanoma, liver, kidney, pancreatic, esophageal, stomach, ovarian, cervical or lymphoma tumors. Treatment of
30 breast, colon, lung, and prostate tumors is particularly contemplated. Treatment of leukemias is also contemplated. The composition may be administered to a patient afflicted with cancer and/or leukemia by any conventional route of administration, as discussed above.

The method is useful to slow the growth of tumors, prevent tumor growth, induce partial regression of tumors, and induce complete regression of tumors, to the point of complete disappearance. The method is also useful in preventing the outgrowth of metastases derived from solid tumors.


- 5 The compositions of the invention may be administered as sole therapy or with other supportive or therapeutic treatments not designed to have anti-cancer effects in the subject. The method also includes administering the invention compositions in combination with one or more conventional anti-cancer drugs or biologic protein agents, where the amount of drug(s) or agent(s) is, by itself, ineffective to induce the appropriate
- 10 suppression of cancer growth, in an amount effective to have the desired anti-cancer effects in the subject. Such anti-cancer drugs include actinomycin D, camptothecin, carboplatin, cisplatin, cyclophosphamide, cytosine arabinoside, daunorubicin, doxorubicin, etoposide, fludarabine, 5-fluorouracil, hydroxyurea, gemcitabine, irinotecan, methotrexate, mitomycin C, mitoxantrone, paclitaxel, taxotere, teniposide,
- 15 topotecan, vinblastine, vincristine, vindesine, and vinorelbine. Anti-cancer biologic protein agents include tumor necrosis factor (TNF), TNF-related apoptosis inducing ligand (TRAIL), other TNF-related or TRAIL-related ligands and factors, interferon, interleukin-2, other interleukins, other cytokines, chemokines, and factors, antibodies to tumor-related molecules or receptors (such as anti-HER2 antibody), and agents that react
- 20 with or bind to these agents (such as members of the TNF super family of receptors, other receptors, receptor antagonists, and antibodies with specificity for these agents).

EXAMPLES

The following examples illustrate but are not intended in any way to limit the

25 invention.


General Procedure for Esterification of Triptolide with Protected Amino Acids



Protected amino acid (1.0 mmol, 5 eq) in dichloromethane (2 ml) is treated under

- nitrogen with 1,3-dicyclohexylcarbodiimide (DCC) (2.0 mmol, 10 eq) at room temperature for two hours. A solution of triptolide (0.2 mmol, 1 eq) and 4-dimethylaminopyridine (DMAP) (2.2 mmol, 11 eq) in dichloromethane (2 ml) is then added. The reaction mixture is stirred under nitrogen overnight. After the removal of the precipitate by filtration, the crude product is purified by preparative TLC. An α -amino acid is depicted above; β - and higher amino acids can also be used, as shown in the Examples below. Similar reactions could also be carried out with protected oligopeptides having a free carboxy terminus.


10 Example 1: Synthesis of Triptolide 14-N-t-Butoxycarbonyl- α -t-butyl-L-glutamate Ester (PG658)



Using the above General Procedure, the product is obtained in 92% yield from N-tert-butoxycarbonyl- α -tert-butyl-L-glutamic acid and triptolide.

- 15 Analytical TLC R_f = 0.59 (ethyl acetate/hexanes/methanol 1:1:0.1). IR (KBr): 3387.1, 2983.6, 2937.1, 2882.8, 1750.0, 1509.5, 1462.9, 1377.6, 1160.3, 1028.4, 873.3, 780.2, 562.9 cm^{-1} . ^1H NMR (300 MHz, CDCl_3): 5.17 (1H, d, NH), 5.08 (1H, d, 14-CH), 4.68 (2H, s, 19- CH_2), 4.16 (1H, m, NCH), 3.83 (1H, d, 11-CH), 3.54 (1H, d, 12-CH), 3.47 (1H, d, 7-CH), 2.23 (3H, m, 5-CH and CH_2), 2.43 [2H, m, CH_2 (next to NCH)], 2.18 (2H, m, 6- CH_β and 2- CH_β), 2.00 (1H, m, 2- CH_α), 1.90 (2H, m, 6- CH_α and 15-CH), 1.58 (1H, m, 1- CH_β), 1.47 (9H, s, t-Bu), 1.44 (9H, s, t-Bu), 1.22 (1H, m, 1- CH_α), 1.06 (3H, s, 20- CH_3), 0.96 (3H, d, 17- CH_3), 0.84 (3H, d, 16- CH_3) ppm.

Example 2: Synthesis of Triptolide 14- α -Benzyl-N-benzyloxycarbonyl-D-glutamate Ester (PG660)




Using the above General Procedure, the product is obtained in 57% yield from α -benzyl-N-benzyloxycarbonyl-D-glutamic acid and triptolide.

Analytical TLC R_f = 0.50 (ethyl acetate/hexanes/methanol 1:1:0.1). IR (KBr): 3376.8, 2977.5, 2944.1, 1749.1, 1683.1, 1529.1, 1463.1, 1265.2, 1221.2, 1177.2, 1030.5, 759.3, 700.0. ¹HMR (300 MHz, CDCl₃): 7.35 (10H, m, 2Ph), 5.53 (1H, d, NH), 5.16 (2H, s, CH₂Ar), 5.10 (2H, s, CH₂Ar), 5.06 (1H, d, 14-CH), 4.66 (2H, s, 19-CH₂), 4.49 (1H, m, NCH), 3.80 (1H, d, 11-CH), 3.49 (1H, d, 12-CH), 3.44 (1H, d, 7-CH), 2.66 (1H, m, 5-CH), 2.52 (2H, t, CH₂), 2.31 [2H, m, CH₂ (next to NCH)], 2.13 (2H, m, 6-CH β and 2-CH β), 2.02 (1H, m, 2-CH α), 1.85 (2H, m, 6-CH α and 15-CH), 1.54 (1H, dd, 1-CH β), 1.20 (1H, m, 1-CH α), 1.00 (3H, s, 20-CH₃), 0.93 (3H, d, 17-CH₃), 0.80 (3H, d, 16-CH₃).

15

Example 3: Synthesis of Triptolide 14- γ -Benzyl-N-benzyloxycarbonyl-(L)-glutamate Ester, mixture with D-isomer (PG657)




Using the above General Procedure, the title compounds are obtained as a diastereomeric mixture in 49% yield from γ -benzyl-N-benzyloxycarbonyl-L-glutamic acid and triptolide. Partial racemization of the L-amino acid occurs during the reaction.

Analytical TLC R_f = 0.49 (ethyl acetate/hexanes/methanol 1:1:0.1). IR (KBr): 3368.4, 3038.6, 2975.4, 2940.4, 2884.2, 1761.4, 1529.9, 1452.6, 1178.9, 1031.6, 757.9,

708.8 cm^{-1} . ^1H NMR (300 MHz, CDCl_3): 7.34-7.07 (10H, m, 2Ph), 5.60-5.30 (1H, m, NH), 5.10-4.94 (5H, m, $2\text{CH}_2\text{Ar}$ and 14-CH), 4.71-4.46 (3H, m, 19- CH_2 and NCH), 3.80-3.79 (1H, m, aliphatic), 3.53-3.44 (2H, m, aliphatic), 2.65-0.74 (21H, m, aliphatic).

5 Example 4: Synthesis of 14- β -Benzyl-N-benzylloxycarbonyl-(L)-aspartate Triptolide Ester, mixture with D-isomer (PG659)




Using the above General Procedure, the title compounds are obtained as a diastereomeric mixture in 89% yield from β -benzyl-N-benzylloxycarbonyl-L-aspartic acid and triptolide.

10 Partial racemization of the L-amino acid occurs during the reaction.

Analytical TLC R_f = 0.50 (ethyl acetate/hexanes/methanol 1:1:0.1). IR (KBr): 3380.9, 3038.6, 2977.2, 2943.6, 2883.0, 1759.3, 1510.3, 1355.5, 1207.5, 1180.6, 1032.5, 992.1, 756.6, 702.8 cm^{-1} . ^1H NMR (300 MHz, CDCl_3): 7.35-7.33 (10H, m, 2Ph), 5.91-5.79 (1H, m, NH), 5.21-5.03 (5H, m, $2\text{CH}_2\text{Ar}$ and 14-CH), 4.81-4.60 (3H, m, 19- CH_2 and 14-CH), 3.81-3.73 (1H, m aliphatic), 3.53-3.44 (2H, m, aliphatic), 3.24-2.94 (2H, m, aliphatic), 2.69-2.65 (1H, m, aliphatic), 2.34-0.69 (16H, m, aliphatic).

15 Example 5: Synthesis of Triptolide 14-N-tert-Butoxycarbonyl- β -tert-butyl-(L)-aspartate Ester, mixture with D-isomer (PG664)



20


Using the above General Procedure, the title compounds are obtained as a diastereomeric mixture in 81% yield from β -benzyl-N-benzylloxycarbonyl-L-aspartic acid and triptolide.

Partial racemization of the L-amino acid occurs during the reaction.

Analytical TLC R_f = 0.63 (ethyl acetate/hexanes/methanol 1:1:0.1). ^1H NMR (300

MHz, CDCl₃): 5.62-5.49 (1H, m, NH), 5.08-5.05 (1H, m, 14-CH), 4.74-4.57 (3H, m, 19-CH₂ and NCH), 3.83-3.75 (1H, m, aliphatic), 3.55-3.45 (2H, m, aliphatic), 3.05-2.80 (2H, m, aliphatic), 2.70-2.66 (1H, m, aliphatic), 2.35-0.62 (34H, m, aliphatic).

5 Example 6: Synthesis of 14-γ-L-glutamate Ester of Triptolide (PG661)



14-N-tert-butoxycarbonyl-α-tert-butyl-L-glutamate ester of triptolide (PG 658) (24.2 mg) is treated with trifluoroacetic acid (1 ml) at room temperature overnight. After removal of trifluoroacetic acid under vacuum, the crude product is purified by
 10 preparative TLC (isopropanol:aqueous ammonia 7:3) to give 8.2 mg of title compound.

Analytical TLC R_f = 0.65 (propan-1-ol/aqueous ammonia 7:3) ¹H NMR (300 MHz, C₅D₅N): 6.26 (1H, s, 14-CH), 4.89 (2H, q, 19-CH), 4.66 (1H, d, 7-CH), 4.58 (1H, d, 11-CH), 4.45 (1H, m, NCH), 4.36 (1H, d, 12-CH), 3.62 (3H, s, NH₃⁺), 2.73 (4H, m, COCH₂CH₂), 2.45 (2H, m, 6-CH_β and 15-CH), 2.06 (1H, m, 2-CH_α), 1.66 (1H, m, 2-CH_α),
 15 CH_α), 1.54 (3H, s, 20-CH₃), 1.30 (3H, m, 6-CH_α and 1-CH₂), 1.07 (3H, d, 17-CH₃), 0.93 (3H, d, 16-CH₃). HRMS (FAB) *m/z* calcd for C₂₅H₃₂NO₉⁺ (MH⁺) 490.2077, found 490.2065.

Example 7: Apoptosis Assays

20 A. Incubation of compounds with human serum.

Pooled human serum was stored in aliquots at -80°C. Test compounds were added at 20 mM to thawed human serum in 1.5 ml microfuge tubes and incubated at 37°C in a water bath for 48 hours. The test samples were placed on ice until dilution for the bioassay. Controls consisted of the compounds incubated in complete tissue culture
 25 medium (RPMI 1640 medium plus 5 % heat-inactivated fetal calf serum, 1 % HEPES, 1 % pen/strep, 1 % glutamine) rather than human serum.

B. Terminal deoxynucleotidyl transferase apoptosis assay.

Test samples were diluted to 1 mM in complete tissue culture medium. Aliquots

were placed in microculture plates and serial dilutions were prepared so that the final concentration would encompass the range of 2 to 6,000 nM with half-log increments. Cells from an exponentially expanding culture of the Jurkat human T lymphocyte cell line (#TIB-152 obtained from American Type Culture Collection, Manassas, VA) were
5 harvested, washed once by centrifugation and dilution in complete tissue culture medium, and diluted to a concentration of 1×10^6 cells/ml. A volume of 100 μ l of Jurkat cells (1×10^5 cells) was added to wells containing 100 μ l of the diluted compounds, and the plates were incubated at 37°C in a 5% CO₂ incubator. After 24 hours, the plates were centrifuged to pellet the cells, and the cells were washed with PBS. The cells were fixed
10 in paraformaldehyde, washed, treated with ethanol, washed and then incubated with the enzyme terminal deoxynucleotidyl transferase (TdT) and fluorescein labeled-deoxyuridine (dUTP). The process allows 3' end labeling of DNA molecules which were nicked during the DNA fragmentation phase of apoptosis (terminal deoxynucleotidyl transferase dUTP nick end labeling; TUNEL labeling). The cells were
15 washed, treated with ribonuclease, washed and resuspended in medium containing propidium iodide to distinguish intact apoptotic cells. The contents of the assay wells were individually transferred into test tubes, and apoptosis was analyzed using a FACSCalibur flow cytometer (BD Immunocytometry Systems, San Jose, CA). Cells positive for FI-dUTP were considered to be apoptotic, and the data were calculated as
20 percent apoptotic cells.

C. Annexin V apoptosis assay.

Test samples (incubated in human serum as described in section A) were prepared and diluted as described in section B, and Jurkat human T lymphocyte cells were prepared and added to wells containing 100 μ l of the diluted compounds, also as
25 described in section B. The plates were incubated at 37°C in a 5% CO₂ incubator. After 24 hours, the plates were centrifuged to pellet the cells, and the cells were washed twice with 2% heat-inactivated fetal calf serum in PBS. To each well, 500 μ l of binding buffer was added, according to the Annexin V assay procedure (BioVision, Inc., Mountain View, CA). Next, 5 μ l of the fluorescein isothiocyanate (FITC) conjugate of Annexin V
30 (BioVision, Inc.) was added to each well, followed by 5 minutes of incubation in the dark. In some assays, propidium iodide (BioVision, Inc.) was added at this stage to check for necrotic cells. The contents of the wells were individually transferred into test

tubes, and apoptosis was analyzed using a FACSCalibur flow cytometer (BD Immunocytometry Systems, San Jose, CA). Cells positive for Annexin V binding were considered to be apoptotic, and the data were calculated as percent apoptotic cells.

For the assays in sections B and C, data were plotted as the concentration of compound incubated in serum versus percent apoptotic cells, and the concentration of compound inducing 50% apoptosis (ED50) was calculated from these dose response curves. The percent conversion of the test compounds to bioactive compound (assumed to be triptolide) was calculated in reference to the result with triptolide incubated in parallel in human serum in the same experiment, as the percent of the ED50 of the compound compared to that for triptolide, which was taken as 100%.

Example 8: IL-2 Production Assay


Test samples, incubated in human serum as described in Example 7A, were diluted to 1 mM in complete tissue culture medium. Aliquots were placed in microculture plates that had been coated with anti-CD3 antibody (used to stimulate the production of IL-2 by Jurkat cells), and serial dilutions were prepared so that the final concentration would encompass the range of 0.001 to 10,000 nM in log increments. Cells from an exponentially expanding culture of the Jurkat human T lymphocyte cell line (#TIB-152 obtained from American Type Culture Collection, Manassas, VA) were harvested, washed once by centrifugation and dilution in complete tissue culture medium, and diluted to a concentration of 2×10^6 cells/ml. A volume of 50 μ l of Jurkat cells (1×10^5 cells) was added to wells containing 100 μ l of the diluted compounds, 50 μ l of PMA (10 ng/ml) was added to each well, and the plates were incubated at 37°C in a 5% CO₂ incubator. After 24 hours, the plates were centrifuged to pellet the cells, 150 μ l of supernatant was removed from each well, and the samples were stored at -20°C. The stored supernatants were analyzed for human IL-2 concentration using the Luminex 100 (Luminex Corporation, Austin, TX), Luminex microspheres coupled with anti-IL-2 capture antibody, and fluorochrome-coupled anti-IL-2 detection antibody. The data were expressed as ng/ml of IL-2.

The data were plotted as the concentration of compound incubated in serum versus IL-2 concentration. The concentration of compound inducing a 50% decrease in the IL-2 concentration (IC50) was calculated from these dose response curves. The percent

conversion of the test compound to bioactive compound (assumed to be triptolide) was calculated in reference to the result with triptolide incubated in parallel in human plasma in the same experiment, as the percent of the IC₅₀ of the compound compared to that for triptolide, which was taken as 100%.

IT IS CLAIMED:


1. A compound having the structure:




wherein

- 5 X^1 is OH or OR^1 , and X^2 and X^3 are independently OH, OR^1 or H, with the proviso that at least one of X^1 , X^2 and X^3 is OR^1 , and at least one of X^2 and X^3 is H; and


R^1 is selected from the group consisting of:



10



(c)



(d)

and

- 15 (e): $[C(=O)CHY-NH]_z-C(=O)CHY-NHP^1$;

wherein:

Y is a side chain of a naturally occurring amino acid or a one- or two-carbon homolog thereof;

P^1 is selected from the group consisting of H, $C(=O)OR^2$, and $C(=O)R^3$, wherein

- 20 each of R^2 and R^3 is independently H, alkyl, alkenyl, aryl, or aralkyl;

m is an integer from 0-5;

n is an integer from 0-5;

z is an integer from 2-10;

and

P² is selected from the group consisting of H, alkyl, alkenyl, aryl, or aralkyl.

2. A compound as recited in claim 1, wherein the chiral α -carbon bearing the nitrogen atom, in each of groups (a) - (d), is of the L configuration.


5

3. A compound as recited in claim 1, wherein the chiral α -carbon bearing the nitrogen atom, in each of groups (a) - (d), is of the D configuration.


4. The compound in claim 1, wherein Y is a side chain of a naturally occurring
10 amino acid.

5. A compound as recited in claim 1, wherein X² = X³ = H.

6. A compound as recited in claim 5, wherein R¹ is selected from



7. A compound as recited in claim 6, wherein R¹ is



8. A compound as recited in claim 1, wherein P¹ and P² are both non-hydrogen.

9. A compound as recited in claim 8, wherein R² and R³ are both non-hydrogen.

25 10. A method of anticancer treatment, comprising administering to a subject in need of such treatment, in a pharmaceutically acceptable vehicle, a compound in accordance

with claim 1, or a pharmaceutically acceptable salt thereof.

11. The method of claim 10, wherein said treatment comprises inhibition of tumor growth.

5

12. The method of claim 11, wherein said treatment is directed to the colon, breast, lung, or prostate.

13. A method of effecting immunosuppression, comprising administering to a subject
10 in need of such treatment, a compound in accordance with claim 1, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable vehicle.

14. The method of claim 13, wherein said immunosuppression comprises inhibition of transplant rejection.

15

15. The method of claim 13, wherein said immunosuppression comprises inhibition of graft-versus-host disease.

16. The method of claim 13, wherein said immunosuppression comprises treatment
20 of an autoimmune disease.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/07834

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : CO7D 307/93; A61K 31/343; A61P 35/00

US CL : 514/468; 549/296

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/468; 549/296

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAS-STN ONLINE**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 6,004,999 A (JUNG, et al) 21 December 1999 (21.12.1999), see entire reference.	1-16
A	US 5,663,335 A (QI, et al) 04 September 1997 (04.09.1999), see entire reference.	1-16

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	"T"
"A" document defining the general state of the art which is not considered to be of particular relevance	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

01 May 2002 (01.05.2002)

Date of mailing of the international search report

05 JUN 2002

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Valerie Bell-Harris for
Andrea D. Small

Telephone No. (703) 308-1235